UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  April 18, 2013

 

Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

Delaware     000-54365     20-8133057
(State or other jurisdiction of incorporation)     (Commission File No.)     (IRS Employer Identification No.)

 

605 Third Avenue, 34th Floor  
New York, NY 10158
(Address of principal executive offices) (Zip Code)

 

(646) 666-3188

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The 2013 Annual Meeting of Stockholders (the “Meeting”) of Brainstorm Cell Therapeutics Inc. (the “Company”) was held at the offices of BRL Law Group LLC, 425 Boylston Street, 3rd Floor, Boston, MA 02116 on April 18, 2013. At the Meeting, the following matters were voted upon by the stockholders of the Company:

 

  1. The election of seven directors (listed below) until the next annual meeting of stockholders.
  2. The authorization of the Board of Directors of the Company, in its discretion, should it deem it to be appropriate and in the best interests of the Company and its stockholders, to amend the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of common stock by a ratio of between 1-for-10 and 1-for-20, inclusive, without further approval or authorization of the Company’s stockholders.
  3. The ratification of the appointment of Brightman Almagor & Zohar Co., a member of Deloitte Touche Tohmatsu, as the Company’s independent registered public accounting firm for the current fiscal year.

 

The number of shares of common stock issued, outstanding and eligible to vote at the Meeting as of the record date of March 11, 2013 was 151,260,480. Each of the matters voted upon at the Meeting was approved by the requisite number of votes. The final results of the voting on each of the matters presented to stockholders at the Meeting are as follows:

  

   VOTES 
FOR		   VOTES
WITHHELD		   VOTES
AGAINST		   ABSTENTIONS   BROKER
NON-
VOTES		 
1. Election of seven directors:                         
Dr. Irit Arbel   51,097,132    898,764    N/A    N/A    36,939,016 
Mordechai Friedman   51,097,132    898,764    N/A    N/A    36,939,016 
Dr. Abraham Israeli   51,872,691    123,205    N/A    N/A    36,939,016 
Alon Pinkas   51,096,632    899,264    N/A    N/A    36,939,016 
Chen Schor   51,872,196    123,700    N/A    N/A    36,939,016 
Dr. Robert Shorr   51,876,691    119,205    N/A    N/A    36,939,016 
Malcolm Taub   51,852,691    143,205    N/A    N/A    36,939,016 
                          
2. Approve reverse stock split   85,309,582    N/A    3,477,873    147,457    N/A 
                          
3. Ratification of Brightman Almagor Zohar & Co.   87,110,167    N/A    1,748,745    76,000    N/A 

 

 
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

April 23, 2013 Brainstorm Cell Therapeutics Inc.

 

    
  By:   /s/ Liat Sossover
 

Liat Sossover

  Chief Financial Officer